Biogen nelle notizie
Pioniere globale dei farmaci biotecnologici
Tamtam ha trovato 20 articoli recenti su Biogen.
- Biogen: Why I'm Still Bullish Despite Market Turmoil (NASDAQ:BIIB)
- Biogen (BIIB) PT Raised to $271 at Mizuho
- H.C. Wainwright reiterates Buy rating on Biogen stock at $270
- Eisai and Biogen Present Clarity AD Analysis Showing Lecanemab Slows Decline in Early Alzheimer’s Disease Patients With α-Synuclein Co-Pathology
- Biogen unblurs life with Friedreich ataxia in patient-centered Skyclarys campaign
- Can Biogen (NASDAQ:BIIB) Strengthen Lecanemab Case With Biomarker Data?
- Biogen says low dose of its experimental tau-reducing drug fares even better after nearly 2 years
- Eisai and Biogen Report Three-Year Real-World LEQEMBI Data Showing Slower Alzheimer’s Progression in LEADER Study
- Biogen to Participate in December Healthcare Conferences
- NICE initial recommendation not to approve tofersen
- Biogen reports two-year data for Alzheimer's drug diranersen
- Biogen: 3 Key Takeaways for Long-Term Investors
- Biogen (BIIB) Reports Promising Phase 2 CELIA Trial Results for Early Alzheimer's Therapy
- Diranersen shows 38% clinical decline slowing a...
- Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
- Biogen’s Diranersen Data Show Slower Alzheimer’s Decline Over Two Years
- Biogen reports positive two-year data for Alzheimer’s drug By Investing.com
- Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
- Biogen releases new mid-stage data for early Alzheimer's asset diranersen
- The Rosen Law Firm, P.A. Announces Proposed Class Action
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Biogen?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili